Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Neoadjuvant Study in HER2+ Breast Cancer
NCT03735966Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Henan Cancer Hospital. Started Nov 2018; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03735966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735966.